{"schema_version":"secwatch.filing_event.v1","accession":"0001932393-23-000007","form_type":"8-K","ticker":"GEHC","cik":"0001932393","company_name":"GE HealthCare Technologies Inc.","filed_at":"2023-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.463463+00:00","generated_at":"2026-06-20T06:50:25.914307+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GE HealthCare Q4 revenue $4.9B, adj EPS $1.31; FY23 adj EPS guidance $3.60-$3.75","bullets":["Q4 revenue $4.9B (+8% reported, +13% organic); net income $554M, EPS $1.21, adjusted EPS $1.31.","FY22 revenue $18.3B (+4% reported, +7% organic); net income $1.9B, EPS $4.18, adjusted EPS $4.63.","FY23 guidance: organic revenue growth 5-7%, adj EBIT margin 15.0-15.5%, adj EPS $3.60-$3.75, FCF conversion 85%+.","Cash from operations $2.1B, free cash flow $1.8B for FY22; cash conversion 111%.","Announced agreement to acquire IMACTIS to strengthen interventional guidance capabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001932393-23-000007","json":"https://secwatch.observer/filing/0001932393-23-000007.json","markdown":"https://secwatch.observer/filing/0001932393-23-000007.md","text":"https://secwatch.observer/filing/0001932393-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000007/0001932393-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000007/gehc-20230130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:50:25.914307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90d0b6ba85d3ab4d0622fad243580e4f6db855c8","claim":"GE HealthCare Technologies Inc. reported Fourth quarter and full year ended December 31, 2022 results: revenue Revenues of $4.9 billion, net income Net income was $554 million, EPS Earnings per share (EPS) from continuing operations were $1.21. Guidance reaffirmed.","evidence_excerpt":"access to care, and an aging population globally. We are well positioned to deliver on our 2023 commitments.” Fourth quarter 2022 total financial performance • Revenues of $4.9 billion increased 8% and 13% on an Organic basis* year-over-year, driven by growth in Imaging, Patient Care Solutions (PCS), and Ultrasound. Acquisitions favorably impacted total revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000007/0001932393-23-000007-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"Revenues of $4.9 billion"},{"label":"Net income","value":"Net income was $554 million"},{"label":"EPS","value":"Earnings per share (EPS) from continuing operations were $1.21"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}